This report was first published by Endpoints News. To see the original version, click here
A handful of biotech startups have recently taken an increasingly popular route of financing: extending existing rounds rather than taking on a whole new fundraising campaign.
If “money is like oxygen for biotechs,” in the words of Alveus CEO Raj Kannan, funding-round top-ups are a faster, easier way to catch a quick breath.
您已阅读8%（415字），剩余92%（4620字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。